Skip to main content

The Inhibition of Neurotransmitter Release by Alpha-synuclein

Although current therapy manages the symptoms of Parkinson's disease, we still understand very little about the underlying mechanism of degeneration, and hence have no treatment that addresses the eventual disease progression.

Recent work has shown that the protein alpha-synuclein has a central role in the development of Parkinson's disease. However, the mechanism by which synuclein contributes to degeneration remains entirely unknown. Synuclein localizes to the nerve terminal, suggesting a role in neurotransmitter release at the synapse, but previous work has not yielded conclusive evidence about its physiological role. We have now identified a clear effect of alpha-synuclein on the normal function of the nerve terminal, and will use this as an entry point to understand the physiological role of this protein. Since simple overexpression of alpha-synuclein appears sufficient to cause PD, the results have direct relevance for neural degeneration.

Final Outcome

Dr. Edwards identified a novel role for alpha-synuclein in the regulation of vesicular trafficking and neurotransmitter release.


  • Robert H. Edwards, MD

    San Francisco, CA United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.